Suzetrigine, marketed as Journavx by Vertex Pharmaceuticals, has received FDA approval as a non-addictive treatment for pain following surgery or injury. Unlike opioids, it operates by blocking pain signals outside the brain, marking a breakthrough in pain management. Clinical trials with approximately 2,000 patients show that suzetrigine is as effective as opioid alternatives like Vicodin, yet it lacks severe side effects such as drowsiness. Priced at $15.50 per pill, it presents a controversial cost compared to traditional pain medications.
Suzetrigine, developed by Vertex Pharmaceuticals, blocks pain signals outside the brain, offers a non-addictive alternative to traditional opioids, simplifying pain management.
FDA approval of suzetrigine presents a significant step towards non-addictive pain relief, as expectations grow for powerful alternatives to opioids in managing post-surgical pain.
Collection
[
|
...
]